Vial T, Grignon M, Daumont M, Guy C, Zenut M, Germain M L, Jaubert J, Ruivard M, Guyotat D, Descotes J
Centre Antipoison-Centre de Pharmacovigilance de Lyon, 162 avenue Lacassagne, 69424 Lyon, France.
Eur J Haematol. 2004 May;72(5):358-60. doi: 10.1111/j.1600-0609.2004.00217.x.
To describe cases of fusidic acid-associated sideroblastic anaemia from the French Pharmacovigilance database.
Six cases of sideroblastic anaemia associated with oral fusidic acid treatment were retrieved. Four females and two males (mean age 65.3 yr) developed severe anaemia (mean haemoglobin level: 6.9 g/dL) within 32-190 d (mean: 81 d) of treatment. Bone marrow aspirates showed dyserythropoiesis and ringed sideroblasts in all patients. Four patients required repeated blood transfusions. After fusidic acid discontinuation in five patients, complete recovery was obtained. In one patient, rechallenge with fusidic acid resulted in recurrence of anaemia that resolved after definitive discontinuation of the drug.
Our data indicate that fusidic acid should be added to the list of drugs that can cause sideroblastic anaemia.
从法国药物警戒数据库中描述夫西地酸相关的铁粒幼细胞贫血病例。
检索到6例与口服夫西地酸治疗相关的铁粒幼细胞贫血病例。4名女性和2名男性（平均年龄65.3岁）在治疗32 - 190天（平均81天）内出现严重贫血（平均血红蛋白水平：6.9 g/dL）。所有患者的骨髓穿刺显示红细胞生成异常和环形铁粒幼细胞。4名患者需要反复输血。5名患者停用夫西地酸后完全康复。1名患者再次使用夫西地酸导致贫血复发，在最终停药后贫血症状缓解。
我们的数据表明，夫西地酸应被列入可导致铁粒幼细胞贫血的药物清单中。
